Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
630.16B
Market cap630.16B
Price-Earnings ratio
29.73
Price-Earnings ratio29.73
Dividend yield
2.06%
Dividend yield2.06%
Average volume
6.98M
Average volume6.98M
High today
$261.60
High today$261.60
Low today
$254.99
Low today$254.99
Open price
$255.15
Open price$255.15
Volume
5.73M
Volume5.73M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$184.66
52 Week low$184.66

Stock Snapshot

With a market cap of 630.16B, Johnson & Johnson(JNJ) trades at $261.20. The stock has a price-to-earnings ratio of 29.73 and currently yields dividends of 2.06%.

As of 2026-10-09, Johnson & Johnson(JNJ) stock has fluctuated between $254.99 and $261.60. The current price stands at $261.20, placing the stock +2.4% above today's low and -0.2% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 5.73M, compared to an average daily volume of 6.98M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

JNJ News

TipRanks 8h
Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

AbbVie (ABBV), Johnson & Johnson (JNJ), and Medtronic (MDT) are three healthcare companies with established dividend-growth records and deserve a closer look. A...

TipRanks 11h
Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE, the first and only targeted oral peptide that precisely...

TipRanks 12h
Johnson & Johnson price target raised to $282 from $278 at BofA

BofA raised the firm’s price target on Johnson & Johnson to $282 from $278 and keeps a Neutral rating on the shares as part of the firm’s Q3 EPS preview for its...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

NPR 13h
A student hated reading for years. Her podcast explores finding the right diagnosis - NPR

...

A student hated reading for years. Her podcast explores finding the right diagnosis - NPR
Simply Wall St 24h
What Do Johnson & Johnson Trial Wins Mean For Its Drug Pipeline?

Johnson & Johnson (NYSE: JNJ) reported new long term CARVYKTI data showing five year survival and remission in early line multiple myeloma without maintenance t...

What Do Johnson & Johnson Trial Wins Mean For Its Drug Pipeline?
The Motley Fool 1d
Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect

Johnson & Johnson (JNJ -1.78%) has many qualities. It is one of the largest healthcare companies in the world and boasts an incredibly diversified business and...

Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
Zacks 1d
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in t...

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
24/7 Wall St. 1d
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not

Investing Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not Pfizer's yield towers over Johnson and Johnson's, but...

Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not
Simply Wall St 2d
Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock?

Johnson & Johnson reported new two-year Phase 3 ICONIC-TOTAL results showing ICOTYDE maintained skin clearance and a consistent safety profile through Week 112...

Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock?
24/7 Wall St. 2d
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?

Investing Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy? Johnson & Johnson just logged its 64th straight year of dividend growth, but b...

Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.